MRMD MARIMED INC.
Medicinal Chemicals & Botanical Products · OTC · SEC CIK 1522767 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY6.5%
TTM net income YoY14.4%
TTM EPS YoY20.0%
Revenue 3-yr CAGR4.8%
Net income 3-yr CAGR—
Margins
Gross margin35.4%
Operating margin-1.7%
Net margin-9.3%
FCF margin5.5%
EBITDA margin3.6%
Returns
ROE-31.6%
ROA-7.7%
ROIC (approx.)-1.8%
Asset turnover0.83x
Leverage & solvency
Liabilities / assets76.3%
Debt / equity1.95x
Current ratio0.90x
Interest coverage-0.34x
Cash quality & payout
Operating cash flow / net income-0.65x
Accruals ratio-12.7%
Payout ratio—
Capex / revenue0.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $44.23M | $41.92M | $39.48M | $41.65M | $40.76M | $39.51M | $37.91M | $38.95M |
| Cost of revenue | $27.07M | $25.70M | $24.20M | $31.15M | $24.40M | $23.58M | $22.82M | $26.29M |
| Gross profit | $17.16M | $16.23M | $15.28M | $10.50M | $16.36M | $15.93M | $15.09M | $12.66M |
| SG&A expense | $6.71M | $6.86M | $6.89M | $6.96M | $6.59M | $6.34M | $6.25M | $6.57M |
| Operating income | $1.22M | $418,000 | $125,000 | -$4.53M | $1.60M | $1.02M | -$910,000 | -$1.47M |
| Interest expense | $2.00M | $2.01M | $1.98M | $2.15M | $1.82M | $1.76M | $1.76M | $1.89M |
| Pretax income | -$744,000 | -$1.55M | -$1.12M | -$7.33M | -$182,000 | -$704,000 | -$2.65M | -$3.32M |
| Income tax | $2.74M | $2.02M | $2.65M | -$2.69M | $2.76M | $691,000 | $2.83M | $4.95M |
| Net income | -$3.50M | -$3.59M | -$3.79M | -$4.63M | -$2.95M | -$1.39M | -$5.51M | -$8.27M |
| EBITDA | $3.42M | $2.72M | $2.28M | -$2.45M | $3.70M | $3.12M | $897,000 | $693,000 |
| EPS (basic) | -0.01 | -0.01 | -0.01 | — | -0.01 | 0.00 | -0.01 | — |
| EPS (diluted) | -0.01 | -0.01 | -0.01 | — | -0.01 | 0.00 | -0.01 | — |
| Weighted avg. shares (diluted) | 403.00M | 399.60M | 397.45M | — | 392.61M | 389.90M | 382.56M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $10.36M | $8.44M | $7.94M | $8.88M | $6.60M | $6.14M | $7.20M | $7.28M |
| Short-term investments | — | — | — | — | — | — | — | $0 |
| Receivables | $9.18M | $9.36M | $9.44M | $9.11M | $7.96M | $7.69M | $9.18M | $8.74M |
| Inventory | $37.57M | $36.67M | $39.30M | $36.60M | $40.04M | $38.83M | $37.56M | $33.49M |
| Current assets | $61.37M | $58.43M | $60.79M | $59.29M | $60.09M | $57.13M | $58.00M | $53.51M |
| PP&E, net | $84.91M | $86.41M | $88.05M | $89.39M | $91.25M | $92.65M | $94.39M | $94.17M |
| Goodwill | $24.00M | $24.00M | $24.00M | $24.00M | $22.66M | $20.05M | $19.48M | $15.81M |
| Intangibles | $14.97M | $15.68M | $16.40M | $17.21M | $18.02M | $20.72M | $21.69M | $18.64M |
| Total assets | $198.31M | $197.23M | $201.19M | $202.56M | $205.60M | $204.37M | $208.00M | $206.99M |
| Current liabilities | $67.96M | $63.75M | $63.76M | $59.07M | $56.58M | $50.94M | $55.31M | $50.01M |
| Long-term debt | $81.89M | $82.67M | $82.54M | $76.04M | $76.24M | $77.48M | $77.36M | $78.19M |
| Total debt | $81.89M | $82.67M | $82.54M | $76.04M | $76.24M | $77.48M | $77.36M | $78.19M |
| Total liabilities | $151.33M | $147.06M | $147.74M | $137.83M | $136.55M | $131.20M | $134.06M | $129.44M |
| Shareholders' equity | $41.97M | $45.15M | $48.41M | $51.87M | $56.15M | $58.74M | $59.60M | $60.30M |
| Net debt | $71.53M | $74.23M | $74.61M | $67.16M | $69.64M | $71.34M | $70.16M | $70.91M |
| Shares outstanding | 404.75M | 401.17M | 398.91M | 396.91M | 394.45M | 392.01M | 388.68M | 381.48M |
| Cash flow statement | ||||||||
| Operating cash flow | $3.49M | $2.22M | $949,000 | $3.43M | $2.68M | $297,000 | $1.29M | -$413,000 |
| Capital expenditure | $245,000 | $298,000 | $373,000 | $33,000 | $559,000 | $309,000 | $266,000 | $1.06M |
| Free cash flow | $3.24M | $1.92M | $576,000 | $3.40M | $2.12M | -$12,000 | $1.03M | -$1.47M |
| Investing cash flow | -$295,000 | -$507,000 | -$753,000 | -$197,000 | -$514,000 | -$554,000 | -$115,000 | -$1.20M |
| Financing cash flow | -$1.27M | -$1.21M | -$1.14M | -$944,000 | -$1.70M | -$806,000 | -$1.26M | -$893,000 |
| Depreciation & amortization | $2.20M | $2.30M | $2.15M | $2.07M | $2.10M | $2.10M | $1.81M | $2.16M |
| Stock-based compensation | $335,000 | $350,000 | $325,000 | $382,000 | $382,000 | $549,000 | $547,000 | $278,000 |
Free plan shows the latest 8 periods; Pro shows all 63 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.